ГоловнаArchive of numbers2014Volume 22, issue 2(79)The role of inl ammation in amyotrophic lateral sclerosis: two sides of the same coin
Title of the article The role of inl ammation in amyotrophic lateral sclerosis: two sides of the same coin
Authors Voloshyna Natalia
Yegorkina Olga
In the section PROBLEMATIC ARTICLES
Year 2014 Issue Volume 22, issue 2(79) Pages 5-10
Type of article Scientific article Index UDK 616.832.522-002 Index BBK -
Abstract Amyotrophic lateral sclerosis (ALS) is a neurodegenerative dis-order that results in the selective death both lower and upper motor neurons. The loss of motor neurons and the activation of the immune system form a vicious circle, and the role played by neuroinl ammation, either positive or negative, is still subject to discussion with the sup-port of the dual role or dif erentiated activation of microglia. The i ndings suggest that the active participation of both pro- and anti-inl ammatory cytokines in the implementation of the patho-logical process in ALS. In conditions of microglial activation, we noted the intense expression of pleiotro-pic IL-4  on the background of the moderate increase of expression of proinflammatory cytokines IL-1β, IL-6  and TNF-α, indicating that it does not perform a neuroprotective function and does not exclude its role in the induction of apoptosis
Key words Amyotrophic lateral sclerosis, neuroinl ammation, cytokines.
Access to full text version of the article pdf download
Bibliography 1. The instruction on application of a set of reagents for immunoassay for determining the concentration of tumor necrosis factor-alpha. [Instruktsiia po primeneniiu nabora reagentov dlia immunofermentnogo opredeleniia kontsentratsii faktora nekroza opukholei-al'fa]. Novosibirsk: ZAO «Vektor-Best» Publ., 30.09.08. 22 p.
2. The instruction on application of a set of reagents for immunoassay for determining the concentration of human interleukin-1 beta. [Instruktsiia po primeneniiu nabora reagentov dlia immunofermentnogo opredeleniia kontsentratsii chelovecheskogo interleikina-1 beta]. Novosibirsk: ZAO «Vektor-Best» Publ., 15.10.08. 23 p. 3. The instruction on application of a set of reagents for immunoassay for determining the concentration of human interleukin-4. [Instruktsiia po primeneniiu nabora reagentov dlia immunofermentnogo opredeleniia kontsentratsii chelovecheskogo interleikina-4]. Novosibirsk: ZAO «Vektor-Best» Publ., 20.05.08. 23 p.
4. The instruction on application of a set of reagents for the quantitative determination of the human interleukin-6 (IL-6) in biological liquids of the person and cultural environments. [Instruktsiia po primeneniiu nabora reagentov dlia kolichestvennogo opredeleniia chelovecheskogo interleikina-6 (IL-6) v biologicheskikh zhidkostiakh cheloveka i kul'tural'nykh sredakh]. Novosibirsk: ZAO «Vektor-Best» Publ., 20.05.08. 23 p.
5. Baune B.T., Ponath G. Association between cytokines and cerebral MRI changes in the aging brain. J Geriatr Psychiatry Neurol., 2009, 22 (1), pp. 23-34.
6. Beers D.R., Henkel J.S., Zhao W. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain, 2011, 134 (Pt 5). Pp. 1293-1314.
7. Block M.L., Hong J.S. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans., 2007, 35 (Pt 5). Pp. 1127-1132.
8. Cereda C., Baiocchi C., Bongioanni P. TNF and sTNFR1/2 plasma levels in ALS patients. J Neuroimmunol., 2008, 194(1-2). Pp. 123-131.
9. Cereda C., Gagliardi S., Cova E. The Role of TNF-Alpha in ALS: New Hypotheses for Future Therapeutic Approaches. Amyotrophic Lateral Sclerosis, Prof. Martin Maurer (Ed.). InTechOpen, 2012. Pp. 413-436.
10. Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS) Available at: http://clinicaltrials.gov/ct2/show/NCT00326625.
11. Conde J.R., Streit W.J. Microglia in the aging brain. J Neuropathol Exp Neurol., 2006, 65 (3). Pp. 199-203.
12. Drachman D. B., Frank K., Dykes-Hoberg M. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol., 2002, 52(6). Pp. 771-778.
13. Gao H.M., Hong J.S. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol., 2008, 29(8). Pp. 357-65.
14. Gelinas D.S., McLaurin J. PPAR-alpha expression inversely correlates with inflammatory cytokines IL-1beta and TNF-alpha in aging rats. Neurochem Res., 2005, 30(11). Pp. 1369-1375.
15. Godbout J.P., Johnson R.W. Interleukin-6 in the aging brain. J Neuroimmunol., 2004, 147(1-2). Pp. 141-144.
16. Henkel J. S., Beers D.R., Wen S. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med., 2013, 5(1). Pp. 64-79.
17. Keller A.F., Gravel M., Kriz J. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp Neurol., 2011, 228(1). Pp. 69-79.
18. Liu G., Fiala M., Mizwicki M.T. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am J Neurodegener Dis., 2012, 1(1). Pp. 60-74.
19. McGeer P.L., McGeer E.G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve, 2002, 26(4). Pp. 459-470.
20. Moisse K.M., Strong J. Innate immunity in amyotrophic lateral sclerosis. Biochim. Biophys. Acta., 2006, 1762 (11-12). Pp. 1083-1093.
21. Rentzos M., Evangelopoulos E., Sereti E. Alterations of T cell subsets in ALS: a systemic immune activation? Acta Neurol. Scand., 2012, 125(4). Pp. 260-264.
22. Sekizawa T1., Openshaw H., Ohbo K. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci., 1998, 154 (2). Pp. 194-9.
23. Sta M., Sylva-Steenland R.M., Casula M. Innate and adaptive immunity in amyotrophic lateral sclerosis: Evidence of complement activation. Neurobiol Dis., 2011, 42(3). Pp. 211-20.
24. West M., Mhatre M., Ceballos A. The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. J Neurochem., 2004, 91(1). Pp. 133-143.
25. Weydt P., Weiss M.D., Moller T., Carter G.T. Neuro-inflammation as a therapeutic target amyotrophic lateral sclerosis. Curr. Opin. Investig. Drugs., 2002, 3 (12). Pp. 1720-1724.
26. Zhihui Z., Ilieva H., Hallagan L. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest., 2009, 119(11). Pp. 3437-3449.